Clincosm LogoSign in Get a demo

Evaluation of HDL Subfraction Changes and HDL-Associated Enzymes in Liver Failure Patients and Healthy Donors

Sponsor
Akdeniz University (Other)
Overall Status
Completed
CT.gov ID
NCT05958420
Collaborator
(none)
40
Enrollment
1
Location
24.5
Actual Duration (Months)
1.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study aimed to determine high-density lipoprotein (HDL) subfraction profile and HDL-associated enzyme changes in liver failure patients and healthy donors.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Objectives: This study aimed to determine high-density lipoprotein (HDL) subfraction profile and HDL-associated enzyme changes in liver failure patients and healthy donors.

    Materials and Methods: Twenty liver failure patients and twenty healthy donors are selected. Blood samples obtained from all patients prior to transplant will analyzed. HDL subfraction analysis will done by continuous disc polyacrylamide gel electrophoresis. Plasma levels of apolipoprotein A-1 (ApoA-I), cholesteryl ester transfer protein (CETP), and lecithin-cholesterol acyltransferase (LCAT) will determined by enzyme-linked immunosorbent assay.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Actual Enrollment :
    40 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Evaluation of HDL Subfraction Changes and HDL-Associated Enzymes in Liver Failure Patients and Healthy Donors
    Actual Study Start Date :
    Jan 1, 2020
    Actual Primary Completion Date :
    Jan 15, 2022
    Actual Study Completion Date :
    Jan 15, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Group 1

    Patients with liver failure
    Group 2

    Healthy donors

    Outcome Measures

    Primary Outcome Measures

    1. HDL Subfractions [Blood will collected from all patients before surgery]

      Evaluation of HDL Subfractions in groups

    Secondary Outcome Measures

    1. HDL-associated enzymes [Blood will collected from all patients before surgery]

      ApoA1, CETP and LCAT levels in groups

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Liver failure patients
    Exclusion Criteria:

    • patients not giving consent

    • Participants who had oncological and hematological diseases, coronary failure, kidney failure, malnutrition, diabetes, traumatic brain injury, or cadaveric LT and who were using psychoactive medicines or having a respiratory system or CNS diseases were excluded from the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 AkdenizU Antalya Turkey

    Sponsors and Collaborators

    • Akdeniz University

    Investigators

    • Study Chair: İlker O Aycan, Akdeniz University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    İlker Onguc Aycan, Prof. Dr. İlker Öngüç Aycan, Akdeniz University
    ClinicalTrials.gov Identifier:
    NCT05958420
    Other Study ID Numbers:
    • KC-HDL
    First Posted:
    Jul 24, 2023
    Last Update Posted:
    Jul 24, 2023
    Last Verified:
    Jul 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by İlker Onguc Aycan, Prof. Dr. İlker Öngüç Aycan, Akdeniz University
    Liver Failure
    HDL Subfractions
    ApoA1
    CETP
    LCAT
    Additional relevant MeSH terms:
    Liver Failure
    Hepatic Insufficiency

    Study Results

    No Results Posted as of Jul 24, 2023